Search results: (10000)
News Primum non nocere applies not only in medicine: an ecological look at inhalers
According to estimates from the World Health Organization (WHO), around 65 million people worldwide suffer from mild to moderate forms of chronic obstructive pulmonary disease (COPD). The cornerstone of therapy is the inhalation administration of bronchodilator drugs. While there is no doubt that this therapy helps patients, what impact do the propellants in inhalation systems have on the global climate? And is there a sensible solution to this problem?
News Spiolto Respimat System – Innovation for Easier Inhalation
Inhalation delivery is the most preferred method of drug administration in chronic obstructive pulmonary disease and bronchial asthma. The effectiveness of therapy is also conditioned by the correct inhalation technique. The aim of the following article is a brief comparison of inhalation systems, focusing on a new addition to the group of aerosol inhalers.
News Effect of Discontinuing Inhaled Corticosteroids in Patients with COPD in Real Clinical Practice
Inhaled corticosteroids are prescribed to patients with COPD to prevent disease exacerbation. However, in clinical practice, they are often overprescribed in non-indicated cases. A study conducted in real clinical conditions evaluated the effect of discontinuing inhaled corticosteroids compared to continuing triple therapy in patients with COPD.
News Dual therapy improves not only lung function but also quality of life in COPD patients
Chronic obstructive pulmonary disease (COPD) reduces the quality of life of patients and is one of the main causes of morbidity and mortality. According to international recommendations, the initial pharmacotherapy is recommended as monotherapy with LAMA (long-acting muscarinic antagonists) or LABA (long-acting beta-agonists), or their combination. A pooled analysis of 4 studies compared the early addition of LABA to LAMA in patients with moderate to severe COPD.
News Improvement of Physical Functions in Patients with COPD in Routine Clinical Practice Using the Fixed Combination of Tiotropium/Olodaterol
The increase in exercise capacity using the fixed combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies for patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefit under real-world conditions and also focused on patient satisfaction with the inhaler.
News Improving Physical Function in Patients with COPD in Routine Clinical Practice
The increase in exercise capacity with the use of a fixed-dose combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies in patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefits in real-world practice and also focused on patient satisfaction with the inhaler.